Anti-STAT3 (phospho Y705) antibody [EPR23968-52] (Ab267373)
APRF, STAT3, Signal transducer and activator of transcription 3, Acute-phase response factor
详细信息
背景信息
What is this antibody validated in? Anti-STAT3 (phospho Y705) antibody [EPR23968-52] (ab267373) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF), ChIP, Dot Blot in Human samples. What is the molecular weight of STAT3? Anti-STAT3 (phospho Y705) [EPR23968-52] (ab267373) specifically detects a band for STAT3 (UniProt: P40763) at a molecular weight of 88kDa. Trusted by the scientific community Anti-STAT3 (phospho Y705) [EPR23968-52] (ab267373) was first used in a scientific publication in 2021 and has been cited over 40 times in peer-reviewed journals. Specificity confirmed The specificity of Anti-STAT3 (phospho Y705) antibody [EPR23968-52] (ab267373) has been confirmed by Western blot testing in STAT3 Knockout HeLa cell line, ab255436. Other related products We have a range of other formats of antibody clone [EPR23968-52] also available for your convenience: ab267373, Carrier free - ab280202 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (133)
Synergistic anti-hepatoma effect of triptolide and quercetin via co-inhibition and interaction with Janus kinase and mammalian target of rapamycin signal pathway.
雷公藤内酯醇和槲皮素通过与 Janus 激酶和哺乳动物雷帕霉素靶蛋白信号通路的共同抑制和相互作用，发挥协同抗肝癌作用。
Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4/NF-κB/IL-6/STAT3 Signalling Cascade.
外泌体 HMGB1 通过 TLR4/NF-κB/IL-6/STAT3 信号级联调控 NSCLC 进展和免疫抑制性巨噬细胞极化。
Peritoneal MSCs-derived exosomes suppress CCL24 synthesis through miR-320d delivery contributing to the improvement of peritoneal dialysis-associated fibrosis.
腹膜间充质干细胞衍生的外泌体通过 miR-320d 递送抑制 CCL24 合成，从而有助于改善腹膜透析相关纤维化。
IgG Fc binding protein (FCGBP) inhibits the development of laryngeal squamous cell carcinoma and cisplatin resistance through the PIGR/JAK2/STAT3 pathway.
IgG Fc 结合蛋白 (FCGBP) 通过 PIGR/JAK2/STAT3 通路抑制喉鳞状细胞癌的发展和顺铂耐药性。
Targeting OxLDL-mediated CD36â+âCAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.
靶向 OxLDL 介导的 CD36+CAF 重编程可增强 PD-1 免疫疗法在骨肉瘤中的疗效。
Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells.
乳酸化驱动的 USP4 介导的 ANXA2 稳定和激活促进胶质母细胞瘤干细胞的维持和放射抗性
Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer.
靶向肿瘤细胞固有 CTRP6 仿生共递送可协同增强铁死亡和免疫激活，从而提高抗 PD-L1 免疫疗法在肺癌中的疗效
GPX4 knockdown suppresses M2 macrophage polarization in gastric cancer by modulating kynurenine metabolism
GPX4 敲低通过调节犬尿氨酸代谢抑制胃癌中 M2 巨噬细胞的极化。
Deliver CEBPE via cartilage targeting Lipid nanoparticle to block CEBPE-LTF-STAT3 positive feedback loop for efficient treatment of cartilage endplate degeneration.
通过软骨靶向脂质纳米颗粒递送 CEBPE，阻断 CEBPE-LTF-STAT3 正反馈回路，从而有效治疗软骨终板退化
Inhibition of Rho GEFs attenuates pulmonary fibrosis through suppressing myofibroblast activation and reprogramming profibrotic macrophages.
抑制 Rho GEF 可通过抑制肌成纤维细胞活化和重编程促纤维化巨噬细胞来减轻肺纤维化
- 1
- 2
- 3
- 4
- 5
- 6
- 14